TORONTO, Jan. 6 /CNW/ - Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded proteins in brain-wasting diseases and cancer, announced today that Robert Gundel, Ph.D., M.B.A., has been appointed the company's Vice President, Research & Development.
"We are very pleased to attract a scientific and business leader of Robert Gundel's caliber to this key position," commented Dr. George Adams, Chief Executive Officer of Amorfix.
Dr. Gundel has 25 years of drug development experience with both major pharmaceutical and smaller biotechnology companies focusing on therapeutic monoclonal antibodies and vaccines. Before joining Amorfix, Dr. Gundel was the Chief Scientific Officer at Heat Biologics, a clinical stage company developing novel vaccine and monoclonal antibody technologies for the treatment of autoimmune diseases and cancers. Prior to Heat Biologics, Dr. Gundel was the Vice President and Head of Research at Elusys Therapeutics Inc. where he directed all research and development programs in the areas of vaccines, anti-infectives and the anti-anthrax toxin monoclonal antibody, Anthem(TM), being developed in collaboration with the National Institute of Allergy and Infectious Diseases and the Department of Homeland Security for stockpiling as part of the U.S. biodefense program against potential terrorist attacks. Prior to that, Dr. Gundel was the Chief Scientific Officer at Arius Research, Inc. which was recently purchased by Roche. Earlier in his career, Dr. Gundel served as Vice President, Pharmacology and Preclinical Research at Chiron Corporation, Director of Pharmacology at Bayer Corporation, and Vice President, Preclinical Research and Scientific Corporate Development at XOMA (US), LLC. He began his career in pharmaceutical R&D at Boehringer Ingelheim Pharmaceuticals, Inc.
"Robert's extensive record of new product advancement will be a great asset as we continue to discover, develop and commercialize novel diagnostic and therapeutic products based on our Epitope Protection(TM) and ProMIS(TM) technology platforms," said Dr. Neil Cashman, Chief Scientific Officer of Amorfix.
Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting brain-wasting diseases including ALS, Alzheimer's Disease, variant Creutzfeldt-Jakob Disease (vCJD) and Cancer. Amorfix's proprietary Epitope Protection(TM) (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated misfolded proteins are a common element of many brain wasting diseases and the ability to identify AMPs and understand their structure and mechanism of folding are the first steps to developing new treatments for these devastating diseases. Amorfix utilizes its computational discovery platform, ProMIS(TM), to predict novel Disease Specific Epitopes ("DSE") on the molecular surface of misfolded proteins. ProMIS(TM) is an "in silico" rational selection approach that can be applied to any protein where the normal folding structure is at least partially known. Amorfix's lead therapeutic programs include antibodies and vaccines to DSEs in ALS, Alzheimer's disease and Cancer. The Company's diagnostic programs include a blood screening test for vCJD and the A4 test, an ultrasensitive method for the detection of aggregated Beta-Amyloid in brain tissue of animal models of Alzheimer's disease, months prior to plaque formation.
This press release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Amorfix Life Sciences Ltd.
For further information: For further information: Dr. George Adams, President & Chief Executive Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6959, Fax: (416) 847-6899, email@example.com; James Parsons, Chief Financial Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6929, Fax: (416) 847-6899, firstname.lastname@example.org